The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Gut microbiota-derived indole compounds attenuate metabolic dysfunction-associated steatotic liver disease by improving fat metabolism and inflammation
Open accessAbstract
Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most common chronic liver disease, and its prevalence has increased worldwide in recent years. Additionally, there is a close relationship between MASLD and gut microbiota-derived metabolites. However, the mechanisms of MASLD and its metabolites are still unclear. We demonstrated decreased indole-3-propionic acid (IPA) and indole-3-acetic acid (IAA) in the feces of patients with hepatic steatosis compared to healthy controls. Here, IPA and IAA administration ameliorated hepatic steatosis and inflammation in an animal model of WD-induced MASLD by suppressing the NF-κB signaling pathway through a reduction in endotoxin levels and inactivation of macrophages. Bifidobacterium bifidum metabolizes tryptophan to produce IAA, and B. bifidum effectively prevents hepatic steatosis and inflammation through the production of IAA. Our study demonstrates that IPA and IAA derived from the gut microbiota have novel preventive or therapeutic potential for MASLD treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Design and validation of a histological scoring system for nonalcoholic fatty liver disease†
Kleiner, D. E., Brunt, E. M., Van Natta, M., Behling, C., Contos, M. J., Cummings, O. W., Ferrell, L. D., Liu, Y., Torbenson, M. S., Unalp‐Arida, A., et al. (2005) · Hepatology · doi:10.1002/hep.20701 · Cited by 10,791
Gut Microbiota Regulation of Tryptophan Metabolism in Health and Disease
Agus, A., Planchais, J., & Sokol, H. (2018) · Cell Host & Microbe · doi:10.1016/j.chom.2018.05.003 · Cited by 3,180 · cited 2×
“23 The levels of the indoles IPA and IAA tended to decrease in these pathways as MASLD worsened.”
BackgroundThe multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD)
Buzzetti, E., Pinzani, M., & Tsochatzis, E. A. (2016) · Metabolism · doi:10.1016/j.metabol.2015.12.012 · Cited by 3,119
Role of the gut microbiota in nutrition and health
Valdes, A. M., Walter, J., Segal, E., & Spector, T. D. (2018) · BMJ · doi:10.1136/bmj.k2179 · Cited by 2,375 · cited 1×
“7 The intestinal microbiota consists of a large number of strains that belong to phyla such as Firmicutes , Bacteroides , Actinobacteria , Proteobacteria , and Verrucomicrobia .”
BackgroundDiet–microbiota interactions as moderators of human metabolism
Sonnenburg, J. L., & Bäckhed, F. (2016) · Nature · doi:10.1038/nature18846 · Cited by 2,257
Gut microbiota-derived metabolites as central regulators in metabolic disorders
Agus, A., Clément, K., & Sokol, H. (2021) · Gut · doi:10.1136/gutjnl-2020-323071 · Cited by 1,347 · cited 2×
“50 As a result, the underlying cause of the increased bile acids in the feces of patients with hepatic steatosis suggests an impairment of FXR function.”
BackgroundThe role of the gut microbiota in NAFLD
Leung, C., Rivera, L., Furness, J. B., & Angus, P. W. (2016) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2016.85 · Cited by 1,020 · cited 1×
“27 The mechanisms linking obesity and the gut microbiome are being elucidated through a combination of vigorous studies in human and animal models.”
BackgroundKoliada, A., Syzenko, G., Moseiko, V., Budovska, L., Puchkov, K., Perederiy, V., Gavalko, Y., Dorofeyev, A., Romanenko, M., Tkach, S., et al. (2017) · BMC Microbiology · doi:10.1186/s12866-017-1027-1 · Cited by 1,000
Krishnan, S., Ding, Y., Saedi, N., Choi, M., Sridharan, G. V., Sherr, D. H., Yarmush, M. L., Alaniz, R. C., Jayaraman, A., & Lee, K. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.03.109 · Cited by 679 · cited 1×
“14,15 As such, Trp availability is an important factor in controlling protein biosynthesis.”
BackgroundDiversity of Bifidobacteria within the Infant Gut Microbiota
Turroni, F., Peano, C., Pass, D. A., Foroni, E., Severgnini, M., Claesson, M. J., Kerr, C., Hourihane, J., Murray, D., Fuligni, F., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0036957 · Cited by 647 · cited 1×
“47 The genus Bifidobacterium has a fructose-6-phosphate phos-phoketolase pathway used for carbohydrate fermentation.”
Background
Metadata
- Authors
- Min, B. H., Devi, S., Kwon, G. H., Gupta, H., Jeong, J.-J., Sharma, S. P., Won, S.-M., Oh, K.-K., Yoon, S. J., Park, H. J., Eom, J. A., Jeong, M. K., Hyun, J. Y., Stalin, N., Park, T.-S., Choi, J., Lee, D. Y., Han, S. H., Kim, D. J., & Suk, K. T.
- Venue
- Gut Microbes
- Publisher
- Informa UK Limited
- Published
- 2024-02
- Volume
- 16
- Issue
- 1
- Pages
- 2307568-2307568
- ISSN
- 1949-0976 (ISSN-L)
- 1949-0984
- OpenAlex
- W4391447289
- Cited by
- 180
- References
- 13
- FWCI
- 20.91
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Gut microbiota-derived indole compounds attenuate metabolic dysfunction-associated steatotic liver disease by improving fat metabolism and inflammation. https://app.cochat.ai/papers/10.1080/19490976.2024.2307568
- The paper
- Min, B. H., Devi, S., Kwon, G. H., Gupta, H., Jeong, J.-J., Sharma, S. P., Won, S.-M., Oh, K.-K., Yoon, S. J., Park, H. J., Eom, J. A., Jeong, M. K., Hyun, J. Y., Stalin, N., Park, T.-S., Choi, J., Lee, D. Y., Han, S. H., Kim, D. J., & Suk, K. T. (2024). Gut microbiota-derived indole compounds attenuate metabolic dysfunction-associated steatotic liver disease by improving fat metabolism and inflammation. Gut Microbes. https://doi.org/10.1080/19490976.2024.2307568
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.